Tag Archives: targeted therapy

Risk Appetite Returns To Biotech With IBB Up Over 3%

Rayno Life Science Stocks -Green Screen Rules-NASDAQ (4168) Up 1.16% Speculative ETF XBI (134.50) up 4.69% and 7.88% over 5 days; 52 week high $172.52. ETF PBE ($40.85)  up over 3%. Momentum stocks are soaring but way off all time highs in February. Big Rayno Biopharma Movers: ACHN up 8%, ALKS up 3.4%, ARIA up […]

Leave a comment Continue Reading →

Another Green Day For Biotech- Rayno Life Science Movers: ALKS, BIIB, GILD, ILMN, RGDX

Biotech Stocks Have A Strong Day-April 15 Bottom Holding Rayno Life Science Portfolios Stick with larger caps through earnings: ABBV, AMGN, ALKS, BIIB, GILD. MOMO mid cap stocks coming back today: INCY MDVN PBYI plus many others. Losers- Cepheid (CPHD and Pharmacyclics (PCYC) Our biotech portfolio had a strong day with many stocks up 3% […]

Leave a comment Continue Reading →

Biotech Rout Not Surprising: Surveying The Damage

Top Ten Reasons For Biotech Correction NASDAQ at 4022,IBB at 221 A Sentiment Driven Market We have been writing about the bull market in biotech stocks since its inception in March 2009 when quality companies were advancing their pipelines and new products in immunology, oncology and infectious disease were being launched. The life science sector […]

Leave a comment Continue Reading →

Seeking A Technical Bottom For Biotech Stocks….. Update 4/9 Rally

NASDAQ Up 0.37% to 4133 Green screen alert with large cap biotechs. Time to cover hedges. Alexion (ALXN) up 2.23% Biogen (BIIB) Up 2.4% Celgene (CELG) up 3.61% Clovis Oncology (CLVS) up 2.85% Gilead (GILD) up 1.35% IBB up 1.96% Regeneron (REGN) up 3.99% Key Trends To Watch: April Update After Correction We provided a […]

Comments Off Continue Reading →

Biotech Sell-Off Resumes: Caution Update 4/4

Update 4/4/14 Breach of Technicals-A Tad Below Early February Support Glut of Biotech IPOs Causing Indigestion? Momentum Days Are So Over NASDAQ Down 1.34% The volatile and speculative SPDR S&P Biotech XBI hit $136 in early trading down 2.28%.After a brief rally early this week to the $148 level volume picked up with sellers. The […]

Comments Off Continue Reading →

Rayno Biopharmaceutical Stocks Q1 2014 Performance

Rayno Biopharmaceutical Portfolio 3/31/14 Most of our biotech picks did well in a tough quarter that went through a severe correction in early February and again in late March. Many small and mid-cap momentum stocks were crushed but indices (FBT,IBB) overall held the early February technical levels. Use the two ETFs and FBIOX for re-balancing […]

Comments Off Continue Reading →